How has MoonLake Immunotherapeutics's gross unrealized gains changed year-over-year?

MoonLake Immunotherapeutics's gross unrealized gains decreased by 86.3% year-over-year, from $2.65M to $362K.

MoonLake Immunotherapeutics MLTX Gross Unrealized Gains

Oruka Therapeutics, Inc.ORKA

——

Nektar TherapeuticsNKTR

——

Arcutis Biotherapeutics, Inc.ARQT

——

Regeneron PharmaceuticalsREGN

——

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is MoonLake Immunotherapeutics's gross unrealized gains?: MoonLake Immunotherapeutics (MLTX) reported gross unrealized gains of $362K in Q1 2026.
How has MoonLake Immunotherapeutics's gross unrealized gains changed year-over-year?: MoonLake Immunotherapeutics's gross unrealized gains decreased by 86.3% year-over-year, from $2.65M to $362K.